Significant Study: Lixte Biotechnology (LIXT) & Its Friends

Lixte Biotechnology (NASDAQ:LIXT – Get Rating) is a person of 941 publicly-traded firms in the “Pharmaceutical preparations” field, but how does it look at to its rivals? We will review Lixte Biotechnology to identical corporations centered on the energy of its risk, valuation, institutional possession, earnings, profitability, dividends and analyst recommendations.

Profitability

This table compares Lixte Biotechnology and its rivals’ internet margins, return on equity and return on assets.

Valuation & Earnings

This desk compares Lixte Biotechnology and its rivals profits, earnings for every share (EPS) and valuation.

Lixte Biotechnology’s rivals have bigger earnings and earnings than Lixte Biotechnology. Lixte Biotechnology is trading at a larger price tag-to-earnings ratio than its rivals, indicating that it is currently far more high priced than other companies in its industry.

Insider & Institutional Possession

8.8% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 45.1% of shares of all “Pharmaceutical preparations” corporations are owned by institutional traders. 40.7% of Lixte Biotechnology shares are owned by insiders. Comparatively, 15.% of shares of all “Pharmaceutical preparations” firms are owned by insiders. Powerful institutional ownership is an sign that endowments, hedge money and substantial money administrators think a stock is poised for very long-expression expansion.

Analyst Rankings

This is a breakdown of current suggestions for Lixte Biotechnology and its rivals, as described by MarketBeat.

As a team, “Pharmaceutical preparations” companies have a probable upside of 131.67%. Given Lixte Biotechnology’s rivals larger probable upside, analysts obviously imagine Lixte Biotechnology has fewer favorable development aspects than its rivals.

Chance & Volatility

Lixte Biotechnology has a beta of -1.2, suggesting that its share rate is 220% less unstable than the S&P 500. Comparatively, Lixte Biotechnology’s rivals have a beta of 1.14, suggesting that their typical share selling price is 14% much more volatile than the S&P 500.

Summary

Lixte Biotechnology rivals conquer Lixte Biotechnology on 6 of the 9 aspects when compared.

Lixte Biotechnology Corporation Profile (Get Score)

Lixte Biotechnology Holdings, Inc. operates as a drug discovery corporation that works by using biomarker know-how to detect enzyme targets linked with significant frequent health conditions and models novel compounds to attack those people targets. The corporation mainly focuses on inhibitors of protein phosphatases that are utilised by yourself and in mix with cytotoxic brokers and/or x-ray and immune checkpoint blockers and encompasses two important types of compounds at many phases of pre-clinical and clinical growth. It develops two series of pharmacologically active medication, which contain the LB-100 sequence that consists of novel buildings for the treatment method of cancers, and vascular and metabolic conditions and LB-200 collection to handle chronic hereditary conditions, this kind of as Gaucher’s illness, as well as most cancers and neurodegenerative ailments. Lixte Biotechnology Holdings, Inc. has a clinical trial analysis settlement with the Moffitt Most cancers Center and Investigation Institute Clinic Inc. collaboration agreement for an investigator-initiated clinical demo with the Spanish Sarcoma Team, as properly as Netherlands Most cancers Institute and Oncode Institute. The company was launched in 2005 and is primarily based in Pasadena, California.

Receive News & Scores for Lixte Biotechnology Day-to-day – Enter your e-mail deal with beneath to acquire a concise day-to-day summary of the most current information and analysts’ rankings for Lixte Biotechnology and connected corporations with MarketBeat.com’s Absolutely free day-to-day e-mail newsletter.